International Biotechnology (LON:IBT) Shares Pass Above Two Hundred Day Moving Average – Should You Sell?

International Biotechnology (LON:IBT) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of GBX 686.23 ($8.48) and traded as high as GBX 710 ($8.77). International Biotechnology shares last traded at GBX 710 ($8.77), with a volume of 48,839 shares changing hands.

International Biotechnology Price Performance

The company has a debt-to-equity ratio of 9.66, a quick ratio of 0.32 and a current ratio of 0.46. The stock has a market capitalization of £262.42 million, a price-to-earnings ratio of 1,479.17 and a beta of 0.21. The company has a fifty day simple moving average of GBX 693.15 and a two-hundred day simple moving average of GBX 686.23.

International Biotechnology (LON:IBT) last posted its quarterly earnings results on Tuesday, November 5th. The company reported GBX (9.16) (($0.11)) EPS for the quarter. International Biotechnology had a return on equity of 6.25% and a net margin of 75.33%. As a group, equities research analysts expect that International Biotechnology will post 0.9435943 earnings per share for the current fiscal year.

International Biotechnology Increases Dividend

The business also recently declared a dividend, which will be paid on Friday, January 24th. Shareholders of record on Thursday, December 19th will be given a GBX 15.56 ($0.19) dividend. This represents a dividend yield of 2.21%. The ex-dividend date of this dividend is Thursday, December 19th. This is a positive change from International Biotechnology’s previous dividend of $14.50. International Biotechnology’s payout ratio is 6,041.67%.

Insider Buying and Selling at International Biotechnology

In other International Biotechnology news, insider Katherine Cornish-Bowden acquired 1,500 shares of the company’s stock in a transaction dated Tuesday, December 17th. The shares were bought at an average cost of GBX 713 ($8.81) per share, with a total value of £10,695 ($13,210.23). Corporate insiders own 4.18% of the company’s stock.

International Biotechnology Company Profile

The Company’s investment objective is to achieve long-term capital growth by investing in biotechnology and other life sciences companies.

The Company will seek to achieve its objective by investing in a diversified portfolio of companies which may be quoted or unquoted and whose shares are considered to have good growth prospects, with experienced management and strong potential upside through the development and/or commercialisation of a product, device or enabling technology.